HARARE – Parliament has stepped up scrutiny of Zimbabwe’s public pharmaceutical supply chain, with the Parliamentary Portfolio Committee on Health and Child Care undertaking a nationwide assessment of the National Pharmaceutical Company of Zimbabwe (NatPharm) to establish whether funding, procurement, storage and distribution challenges are affecting the availability of essential medicines.
The exercise, which began with a visit to the NatPharm facility in Chinhoyi on Monday before moving to Harare, places the country’s medicine supply chain under parliamentary scrutiny at a time when Zimbabwe is seeking to strengthen public health delivery and build greater domestic capacity in pharmaceutical production.
The significance of the exercise lies in Parliament’s oversight role.
Portfolio committees provide a mechanism through which Parliament scrutinises the administration and implementation of Government policies and programmes within their respective sectors. The Health and Child Care Committee is therefore not taking over the management of NatPharm, but is gathering evidence, examining challenges and engaging the responsible authorities on whether the systems supporting medicine availability are functioning effectively.
This makes the current assessment broader than a physical inspection of medicine stocks.
The committee is looking at stock levels and storage capacity, but is also examining operational issues including funding and procurement. These areas are critical because the availability of medicines at a hospital or clinic is dependent on a chain that begins with planning and budgeting and extends through procurement, warehousing, inventory management and distribution.
A breakdown at any stage can ultimately be felt by patients.
For Parliament, the key question is therefore whether the resources, systems and policies supporting NatPharm are adequate to enable the institution to fulfil its role in the public health system.
The funding question is particularly important. Where medicine shortages are linked to inadequate or delayed financing, the issue moves beyond NatPharm’s day-to-day operations and into the broader question of health-sector resource allocation. Similarly, procurement difficulties can point to weaknesses in purchasing processes, supplier arrangements or the availability of foreign currency.
The committee’s regional approach should help provide a more complete picture.
Following Chinhoyi and Harare, legislators are expected to visit NatPharm facilities in Masvingo, Bulawayo and Gweru. Evidence gathered across these centres can help establish whether the challenges are systemic or whether particular problems are concentrated at specific facilities.
That distinction matters when Parliament considers what recommendations should be made to the Executive.
The committee cannot itself run NatPharm or make routine administrative decisions on behalf of the institution. Its value lies in its ability to investigate matters falling within its portfolio, obtain information from responsible authorities, scrutinise the performance of Government programmes and bring identified shortcomings into the parliamentary process.
Its findings can subsequently inform committee reports, recommendations and engagement with the responsible Ministry and other authorities.
In that respect, the NatPharm exercise provides Parliament with an opportunity to connect medicine availability with the wider question of public-sector performance and the use of public resources.
It also comes against the backdrop of Zimbabwe’s efforts to strengthen local pharmaceutical manufacturing and reduce reliance on imported medicines.
That policy direction has strategic importance. Greater domestic production could reduce exposure to international supply disruptions, import costs and external supply constraints. However, increasing local manufacturing capacity will not, on its own, guarantee that medicines reach patients.
Domestic manufacturers still require predictable procurement arrangements, financing, quality assurance and functioning distribution systems. NatPharm, in turn, needs adequate warehousing, inventory management and distribution capacity to move medicines from suppliers to health institutions.
This means Zimbabwe’s pharmaceutical challenge has to be viewed as a value chain rather than as a problem confined to medicine shortages at individual hospitals.
The parliamentary assessment could consequently help identify where weaknesses exist between the allocation of resources and the eventual delivery of medicines to health facilities.
The accountability question is central.
Where public funds are allocated for medicines, Parliament has a legitimate oversight interest in establishing whether those resources are translating into the intended public benefit. The committee can therefore examine the relationship between funding, procurement, stocks and distribution, and use the evidence gathered to engage the Executive on areas requiring corrective action.
The nationwide visits should provide a stronger evidence base for that engagement.
Ultimately, the importance of the exercise will be determined not by the number of facilities inspected, but by what Parliament does with the evidence gathered. If the assessment identifies specific weaknesses in financing, procurement, storage, inventory management or distribution, those findings can provide the basis for targeted recommendations and closer parliamentary scrutiny of the Government’s response.
For Zimbabwe’s health system, the objective is straightforward: a pharmaceutical supply chain that is adequately funded, efficiently managed and capable of ensuring that essential medicines are available where and when they are needed.
The NatPharm assessment therefore represents an important test of parliamentary oversight, not because Parliament is taking over the pharmaceutical system, but because it is using its constitutional oversight role to examine whether the Executive’s systems and resources are delivering the health outcomes they are intended to achieve.
